Welcome to our dedicated page for Candel Therapeutics news (Ticker: CADL), a resource for investors and traders seeking the latest updates and insights on Candel Therapeutics stock.
Candel Therapeutics, Inc. develops clinical-stage multimodal biological immunotherapies for cancer, including off-the-shelf viral immunotherapy platforms based on genetically modified adenovirus and herpes simplex virus constructs. Company news commonly covers aglatimagene besadenovec, also called aglatne or CAN-2409, in prostate cancer and non-small cell lung cancer, and linoserpaturev, or CAN-3110, from its HSV platform in recurrent high-grade glioma.
Updates also include clinical-data presentations, FDA designations or clearances, research-and-development communications, quarterly financial results, financing activity, and Nasdaq inducement grants under the company’s equity plans.
Candel Therapeutics (Nasdaq: CADL) granted a stock option inducement award to new Chief Commercial Officer Mark Sims under Nasdaq Listing Rule 5635(c)(4). The award covers 285,000 shares at an exercise price of $10.03, matching the July 6, 2026 Nasdaq closing price.
Options vest 25% after one year from his start date and 75% in 36 equal monthly installments, subject to continued service. The grant was made under Candel’s 2025 Inducement Plan, adopted by the board on December 24, 2025.
Candel Therapeutics (Nasdaq: CADL) granted a Nasdaq Listing Rule 5635(c)(4) inducement stock option to one new employee on June 30, 2026. The option covers 25,000 shares at a per-share exercise price of $10.30.
The award was granted under Candel’s 2025 Inducement Plan and vests 25% after one year, with the remaining 75% vesting in 36 monthly installments, subject to continued service. Candel is a clinical-stage company developing multimodal viral immunotherapies for solid tumors.
Candel Therapeutics (Nasdaq: CADL) initiated the global pivotal phase 3 AURORA trial of aglatimagene besadenovec (CAN-2409) in metastatic non-squamous NSCLC after progression on pembrolizumab and platinum chemotherapy.
The open-label study will randomize patients 1:1 across >150 sites versus docetaxel, with overall survival as the primary endpoint. Phase 2 data showed 50% of 46 per-protocol patients lived beyond 24 months, and median overall survival of 25.4 months in the intended phase 3 population. The FDA has granted Fast Track Designation, and Parexel will provide global clinical operations support.
Candel Therapeutics (Nasdaq: CADL) appointed Mark Sims as Chief Commercial Officer, effective July 6, 2026, to lead commercial strategy for aglatimagene besadenovec in intermediate- to high-risk localized prostate cancer.
The role supports a planned BLA submission in Q4 2026 and a potential 2027 launch, targeting about 65,000 eligible U.S. patients annually. Candel is using a partnership-driven model with EVERSANA and IDEA Pharma to prepare market access, medical affairs, manufacturing and launch activities.
Candel Therapeutics (Nasdaq: CADL) reported pivotal phase 3 data in The Lancet Oncology for aglatimagene besadenovec (CAN-2409) in localized prostate cancer.
The 745-patient trial met its primary endpoint, showing a 30% improvement in disease-free survival and supporting a planned BLA submission in Q4 2026.
Candel Therapeutics (Nasdaq: CADL) granted inducement stock options to three new employees under its 2025 Inducement Plan, adopted on December 24, 2025.
The awards cover an aggregate of 63,000 shares at an exercise price of $8.30 per share and were approved on May 31, 2026 under Nasdaq Listing Rule 5635(c)(4).
Candel Therapeutics (Nasdaq: CADL) reported extended follow-up from its pivotal phase 3 trial of aglatimagene besadenovec (CAN-2409) in intermediate- to high-risk localized prostate cancer.
The aglatimagene arm showed a 39% improvement in prostate cancer-specific disease-free survival versus placebo and favorable trends across secondary endpoints. Candel plans a BLA submission in Q4 2026.
Candel Therapeutics (Nasdaq: CADL) reported Q1 2026 results and key pipeline updates. The company plans a BLA submission in Q4 2026 for aglatimagene (CAN-2409) in localized, intermediate- to high-risk prostate cancer and a pivotal phase 3 NSCLC trial start in June 2026.
Candel ended Q1 2026 with $194.8 million in cash and cash equivalents and expects runway into Q1 2028. Recent financings include a $100 million equity offering and a $100 million royalty funding agreement tied to potential U.S. approval of aglatimagene.
Candel Therapeutics (Nasdaq: CADL) announced that CEO Paul Peter Tak will present and hold one-on-one investor meetings at two upcoming conferences.
Events include the Stifel 2026 Virtual Targeted Oncology Forum on May 20, 2026, at 10 AM ET and the Jefferies Global Healthcare Conference in New York on June 3, 2026, at 5:30 PM ET. Live webcasts and 90-day replays will be available via the Investors section of candeltx.com.
Candel Therapeutics (Nasdaq: CADL) will host a webcast and conference call on May 15, 2026 at 1:00 PM ET to discuss extended follow-up data from the Phase 3 trial of aglatimagene besadenovec (CAN-2409) in intermediate- to high-risk localized prostate cancer.
The discussion follows an oral plenary presentation at the American Urological Association 2026 Annual Meeting and will include commentary from leading prostate cancer specialists. The archived webcast will be available on the company's website for 90 days.